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ABSTRACT
The stem cells keep us young by endogenously repairing us upon need. They do so by smartly one step
forward towards differentiation while another step backward to nurture the undifferentiated stem cells.
They are building blocks for every organ with a differential rate of repair of worn out tissues. Since stem
cells can be cultured with a normal karyotype, they could be the ideal source for heart repair after
myocardial infarction. As opposed to lower vertebrates and neonatal mice, cardiac regeneration in adult
mammalian heart seems to be difficult to assess with a solid evidence of cytokinesis. It becomes more
difficult to quantify the level of regeneration after myocardial infarction injury against a background of a
large invasion of proliferating inflammatory cells. The question to be raised is how the renewal of a piece
of myocardium follows the time line of picking up cell types in series: cardiomyocytes, endothelial cells,
smooth muscle cells, fibro blast, pacemaker cells, conducting and Purkinje cells to bring the orchestration
of rhythmically contracting and relaxing heart. This review focuses on where we are on the status of heart
repair and cardiac regeneration.
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INTRODUCTION
Human embryonic stem cells within blastocyst
have made us what we are. The stem cells keep us
young by endogenously repairing us upon need.
They do so by smartly one step forward towards
differentiation while another step backward to
nurture the undifferentiated stem cells. This clinic is
on-line and free for all target organs. Thus, they are
building blocks for every organ with differential rate
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of repair of worn out tissues. It was the pioneering
work of Wilmut et al.1 and Thomson et al.2 on the
cloning and the identification of human embryonic
stem cells that initiated a new era for research in
molecular stem cell biology leading to therapeutic
potential. This review focuses on where we are on
the status of heart repair and cardiac regeneration.3
What is the scope of cardiac stem cell research?:
Fig.1 shows the components of this scope:
Perspective: It is aimed to provide cell replacement
therapy to halt progressive heart failure and repair
heart after myocardial infarction (MI).
Potential: Since stem cells can be cultured with a
normal karyotype and regenerative potential, they
could be the source for heart repair after MI.
Microenvironment: Since stem cells are controlled
by a particular microenvironment, it is supported by
feeding cells, basement membrane and biologically
active molecules. Understanding the stem cellenvironment-interaction at the cellular, molecular
and genetic levels forms the basis of biological
repair of heart. The discovery of neural/cardiac
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Fig.1: Scope of stem cell research.

stem cells has opened new opportunity of biological
repair of brain and heart. However, they seem to be
restricted regionally and temporally. It means that
not all stem cells are equivalent. How good the bone

marrow stem cells could home to heart to become
the part of the working myocardium has been tried
but with limited success. How long they would
remain true to myocardium is not warranted.
Tissue Engineering: careful tissue engineering is
required to produce an ideal mix of stem cells for
the biological repair of diseased organs. As stem
cells have the tendency to be transformed into
cancer cells, it could be considered as one of the
sources of tumor-genesis in different target organs.4
Epigenetic inheritance: Of note is the fact that the
genotypes of most cells are similar. Yet they show
diversity in morphology [phenotype] and functions.
It is because the selective expression and repression
of genes that determine the specific properties
of individual cells. What are signals that can
reprogram differentiated cell back to totipotency
need to be fully elucidated?
Ethical issues: Since resources of acquiring stem
cells are many, ethical and social consideration
of biological repair might pose with difficulty.

Fig.2: Schematic representation of key concepts in biological repair of heart.
(a) Shows time course of pre and post natal cardiac regeneration between lower vertebrates and human. Prenatally both
species are regenerative friendly. Humans dissociate markedly from lower vertebrates postnatally.
(b) Is a cardiac mass response to MI between two species showing complete recovery in lower vertebrates.
(c) Shows hyperbolic relationship between regeneration and scar size in response to MI.
(d) Is a model showing how adult cardiomyocytes might regenerate in response to injury?
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Therefore, any use of stem cell therapy should
be subjected to appropriate scientific and ethical
review committee.
Is human heart post-mitotically locked?: We
thought the mammalian heart to be post mitotically
locked to live as long we live.5 However, this has
been challenged with evidence of resident/homing
stem cells for cardiac regeneration. Prenatally,
this phenomenon is working well. However, this
mechanism is switched off postnatal showing the
stage of terminal differentiation. This transition
might be associated with the transformation of
hyperplasia to hypertrophy. DNA replication study
with evidence of cytokinesis in cardiomyocytes
is actively sought as a test of proliferation and
regeneration.6,7 Since cytokinesis could not be
evidenced in most studies, a quantitation of
regeneration is difficult to assess.8,9 Loss of cardiac
mass as a result of MI or progressive heart failure
is a major cause of morbidity and mortality.10
Since human heart is persistently scarred after MI,
the endogenous cardiac regeneration seems to be
inhibited by the scar formation11,12 (Fig.2c).
Can heart be regenerated by cardiac resident and
homing stem cells?: Findings in lower vertebrates
and neonatal mice are encouraging but cardiac regeneration in adult mammalian heart seems to be
harder to assess with solid evidence (Fig.2a and b).
It becomes more difficult to quantify the level of regeneration after MI injury with a background of a
large invasion of proliferating inflammatory cells.
What are tools to assess cardiac regeneration capacity? These include DNA synthesis labeling, transgenic mouse models and genetic lineage tracing
based on molecular markers, multi-isotope imaging mass spectrometry and immunohistochemistry
and flow cytometry. Addition of nucleosides into
the newly formed DNA shows a rate of less than 1%
of cardiac regeneration per year. Non-cardiomyocyte cells like fibroblasts, endothelial cells, smooth
muscle cell and immune cells and lack of evidence
of cytokinesis due to rigid sarcomeric membrane
seem to be confounder how good the regeneration rate could be estimated.13 Interestingly, various methods using a transgenic mouse model with
beta-galactosidase, 14C labeling of cardiomyocyte
nuclei and multi-isotope imaging mass spectrometry showed a renewal rate not more than 1-2% per
year.6,8,9 However, to what extent these rates might
increase after injury is not clear. Comparing mice
with human’s rate of renewal in context of life span,
this low level regenerative capacity may be of significance in humans for on line acute repair of heart.

The question to be raised is how the renewal of a
piece of myocardium follows the time line of picking
up cell types in series: cardiomyocytes, endothelial
cells, smooth muscle cells, fibroblast, pacemaker
cells, conducting and Purkinje cells to bring the
orchestration of rhythmically contracting and
relaxing heart. How do genes encode these various
cellular programs need to be decoded by welldesigned genomic and proteomic methodologies.
This experimentation might show if cardiomyocyte
genome contained a dormant stem cell regeneration
site that could be coaxed for the biological repair of
heart.14,15
What are cellular sources of adult cardiac
regeneration?: Since the DNA-labeling studies did
not show the cellular source of regeneration in
the adult or injured heart, cell transplantation and
genetic lineage tracing based on molecular markers
were tried. Orlic et al.16 were the first to show a 68%
regeneration of the infarcted myocardium in rodents
in response to injection of Lin-c-Kit+ BMCs [Bone
marrow cells]with a delay of 9 days. This showed
that it took 9 days for processing the BMCs to cardiac
cellular commitment, differentiation and functional
maturation. The sad story is that the claims of this
study could not be reproduced no matter how
the cells were isolated and treated.17 BMCs could
have provided paracrine cardioprotective factors
to improve the cardiac function.18 What might be
the underlying mechanisms are not known. Since
cKit BMCs could not regenerate heart, cultured LincKit+ cardiac progenitor cells, however, showed
initially a positive response to regenerate 70% of
adult rodent hearts after MI injury.11 This study
was also not confirmed in adult hearts.19 Uchida
et al20 reported Sca1-derived cells as a source of
myocardial renewal in the murine adult heart.
Further studies showed that Sca-1-expressing cells
in the heart could be endothelial progenitors.21
How good could the Sca-1 lineage –traced CPCs
contribute new cardiomyocytes to injured heart
remains uncertain. However, the emerging
consensus is that both c-Kit+ and Sca-1+ resident
CPCs cannot differentiate and regenerate the heart
with anew contracting myocardium. How to divert
their endothelial programs into cardiomyocyte
lineage remains to be seen. Another member
walks into this family is cardiac – resident SP
cells with a molecular marker of ABC transporter
proteins being able to trans differentiate into
cardiomyocytes, endothelial cells and smooth
muscle cells.22 These three marker proteins can be
used to identify specific population of CPCs to be
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coaxed into the cardiomyocyte lineage. Of note is
the fact that during embryonic development the
true cardiac progenitors Is1+ cells can give rise to all
lineages found in the heart.23 Similarly epicardially
derived cells differentiate into cardiomyocyte.
How these prenatal programs could be activated
in the adult heart as to be capable of generating
new cardiomyocytes, are not elucidated.24 Genetic
lineage tracing with 15N-thymidine labeling
followed by imaging mass spectroscopy showed
that the mammalian heart can be regenerated
from preexisting cardiomyocytes however, being
limited in potential.9 These cardiomyocytes might
be involved in ongoing renewal, but their response
to the extent of MI seems to be blunted. Since these
cardiomyocytes are also refractory to cytokinesis,
response to MI might depend on this. Factors
blocking cytokinesis could be a genetic block, over
expression of cyclin-D2, Rb proteins deficiency
switching off cardiomyocyte cell cycle activity
and the quantity of nucleation.13,25 These factors
regulating molecular switches of cardiomyocyte
proliferation with a normal cytokinesis should
be experimentally understood as to how scar
formation prevents regeneration of myocardium in
response to MI.
What are challenges in biological repair of heart?:
The real challenge is to gain insights of dynamics
of fetal to adult cardiomyocyte gene expression
encoding proteomics for a well-organized
sarcomeres, t-tubules, and ion channels to ensure
an endogenous repair of adult heart. The delivery
method of cardiac repair is causing uncertainties
in context of either an intravenous injection or
direct coronary infusion of stem cells. The cellular
engraftment rate of injected cells is rather low.
Paracrine mediators like extra cellular matrix
factors angiogenic growth factors and interleukins
among others could stimulate regeneration from
resident cardiac stem cells and/or cardiomyocytes.
How rapidly newly formed cardiomyocytes mature
in vivo/in vitro could provide restoration of cardiac
function with less risk of arrhythmias? How to use
and interpret the time line of cardiomyocyte progeny
with essential cell lines of a beating myocardium?
How to achieve this mission against the tide of risk
factors of rejection, cancer conversion and maturity
are challenges to understand and develop means of
rectification for good news from the clinical trials.
What are implications for biological repair of
heart?: Since the acute biological repair of adult
heart seems to be driven mainly by the proliferation
of cardiomyocytes and to a lesser extent by trans

differentiation of cardiac progenitor cells [CPC],
future line of action should be to therapeutically
focus on these two pathways (Fig.2d). Alternative
cell replacement therapies [CRT] should be
sought to enhance the regenerative capacity of the
myocardium with all functional cell lines enabling
to join the orchestra of a beating heart. Trials with
overall survival as an endpoint are awaited to
ensure CRT to be adopted for the cost effective
biological repair of heart.
What can we learn from cardiac progenitor cellbased trials?: There is an interesting race between
preclinical models and clinical trials. The award of
the former depends on the later. Bolli et al.26 reported
the first trial on autologous cKit+ CPCs from cardiac
tissue being harvested during CABG. These cells
were cultured and then injected through arterial
bypass graft. Large size trial has been recommended
with a cocktail of c-Kit+ CPCs and bone marrow
derived stem cells to reduce infarct size and restore
cardiac function after MI.27 Since the engraftment of
transplanted cells remains low in most of the clinical
trials so far, the potential benefits could be due to
paracrine effect as opposed to transdifferentiation
of injected cells into cardiomyocytes.28 Might it be
possible to study the constituents of the paracrine
mediators to repair heart instead of cell replacement
therapy? On the front line are ES (embryonic stem)
and iPS (induced pluripotent stem) cells to compete
for biological repair of heart. Pre-differentiated-ESpatch has been aimed to align cardiomyocytes with
the ECM to ensue contractile force after adherence
to the native porcine myocardium.29 Human ESCderived-cardiomyocytes have been shown to
regenerate non-human primate hearts.30 The
question arises is might it be possible to switch
fibroblast in the MI-scar into the cardiomyocytes?
Direct reprogramming of fibroblast into functional
cardiomyocytes by factors such as micro-RNA
has been shown by Ieda et al.31 and Jayawardena
et al.32 How far these results from preclinical
animal models could be transferred to human are
challenges of heart repair depending upon good
news from the clinical trials with the endpoint of
appreciable survival.
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